Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
137,162,201
-
Total 13F shares
-
1,863,743
-
Share change
-
+95,239
-
Total reported value
-
$2,590,935
-
Price per share
-
$1.39
-
Number of holders
-
16
-
Value change
-
+$131,897
-
Number of buys
-
6
-
Number of sells
-
7
Institutional Holders of Lucid Diagnostics Inc. - Common Stock, par value $0.001 per share (LUCD) as of Q2 2023
As of 30 Jun 2023,
Lucid Diagnostics Inc. - Common Stock, par value $0.001 per share (LUCD) was held by
16 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,863,743 shares.
The largest 10 holders included
LUMINUS MANAGEMENT LLC, VANGUARD GROUP INC, Nantahala Capital Management, LLC, GEODE CAPITAL MANAGEMENT, LLC, BRIDGEWAY CAPITAL MANAGEMENT, LLC, CITADEL ADVISORS LLC, Verition Fund Management LLC, Geneos Wealth Management Inc., BlackRock Inc., and LPL Financial LLC.
This page lists
16
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.